Arcarine
| Clinical data | |
|---|---|
| Other names | ORM-11984 |
| Drug class | Selective androgen receptor modulator |
Arcarine (ORM-11984) is a selective androgen receptor modulator (SARM) developed by Orion Corporation, a Finnish pharmaceutical company.[1][2][3] It belongs to a class of drugs designed to have tissue-selective androgenic effects, potentially offering the benefits of androgens while minimizing unwanted side effects.[1] Arcarine was investigated for the treatment of various conditions, including benign prostatic hyperplasia, hypogonadism, and osteoporosis.[4][5] The compound reached Phase I clinical trials before development was discontinued.[4] Like other SARMs, Arcarine was developed to potentially provide anabolic effects in muscle and bone tissue while having reduced androgenic effects in other tissues, such as the prostate.[4]
References
[edit]- ^ a b Aro HT, Kulkova J, Moritz N, Kähkönen E, Mattila RH (2015). "Local delivery of a selective androgen receptor modulator failed as an anabolic agent in a rat bone marrow ablation model". Acta Orthopaedica. 86 (6): 751–9. doi:10.3109/17453674.2015.1074840 (inactive 2024-10-20). PMC 4750778. PMID 26198725.
{{cite journal}}: CS1 maint: DOI inactive as of October 2024 (link) - ^ "Research programme: selective androgen receptor modulators (Alternative Names: Arcarine; ORM-11984)". AdisInsight. 4 November 2017. Retrieved 17 October 2024.
- ^ "Delving into the Latest Updates on Arcarine with Synapse". Synapse. 13 October 2024. Retrieved 17 October 2024.
- ^ a b c "Arcarine". Synapse. PatSnap. Archived from the original on 2024-01-14. Retrieved 2024-01-14.
- ^ Xie Y, Tian Y, Zhang Y, Zhang Z, Chen R, Li M, et al. (February 2022). "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)". European Journal of Medicinal Chemistry. 230: 114119. doi:10.1016/j.ejmech.2022.114119. PMID 35063736.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |